Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing and discusses how the dutch biotech ecosystem has evolved.
Arthur Lahr has been part of the Dutch biotech scene for over 15 years now. The former CSO of Crucell, which was sold to J&J in 2011, is now leading Kiadis Pharma as it enters Phase III and approaches the market. “I joined in January and took over as CEO in April, as part of the transition plan,” he explains.
